2022
-
From the Editor: Looking Back on 2022
ILCN Editor Dr. Corey J. Langer reflects on highlights from the past year and looks at the year to come.
-
Updated Guidelines Provide Vital Insights for Pain Management of Cancer Patients
In part 2 of our series on palliative care, expert Dr. Yoshihisa Matsumoto explains why general guides cannot replace therapeutic planning based on careful assessment of an individual patient’s pain.
-
Passing of The Baton—On the Death of Patient Research Advocates
Patient Perspective: We honor those we’ve lost by continuing their advocacy work, patient advocate Angus Pratt says.
-
In Brief for Dec. 21, 2022
IASLC names J. Michael Hoehn COO. FDA approves adagrasib for KRAS G12C-mutated NSCLC. NHS England increases access to screening in effort to catch cancers earlier.
-
Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?
In a “tale of two trials,” Drs. Ogbeide and Osarogiagbon use insights from the ALCHEMIST trial population to try to understand outcomes disparities between North America and Japan.
-
New Screening Approach Needed to Detect Lung Cancer in Patients who Never Smoked
During ACLC 2022, Dr. Gee-Chen Chang made the case for moving beyond smoking history to identify at-risk patients and shared an alternative risk predication model that compared favorably against NLST and NELSON.
-
Palliative Care Benefits Vary Depending on Providers, Timing
In the first of a series of articles on supportive care in lung cancer, Dr. David Hui outlines the needs and reviews evidence-based best practices.
-
In Brief for Dec. 7, 2022
Learn how new guidance from the UK’s National Institutes for Health Care Excellence addresses an unmet clinical need for patients with EGFR+ NSCLC with exon 20 insertion and stay up to date on the latest meeting news from IASLC.
-
Targeted Therapies Expanding for MET Dysregulation in NSCLC
During ACLC 2022, Dr. Noemi Reguart reviewed the data for MET-targeting TKIs and monoclonal antibodies for patients with METex14 skipping mutations, MET amplification, and MET overexpression.
-
Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration
Beyond sotorasib, dozens of small molecule inhibitors are being explored to target this oncogenic driver. Get up to date as researchers from Roswell Park Comprehensive Cancer Center summarize the KRAS trial landscape.
View ILCN Archives
Provider Resources